ArticleClinical rheumatology2026
Clinical and sonographic enthesitis in psoriatic arthritis patients and its relation to serum calprotectin level.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveInvestigate the clinical and sonographic characteristics of enthesitis in psoriatic arthritis (PsA) patients and its relation to psoriatic disease activity and serum calprotectin (CLP).
methodsThis cross-sectional study enrolled PsA patients, diagnosed according to the classification criteria for psoriatic arthritis and an equal number of age and sex matched healthy controls. In PsA patients, enthesitis was assessed clinically using Spondylarthritis Research Consortium of Canada (SPARCC) and sonographically using the Madrid Sonographic Enthesitis Index (MASEI). Serum CLP was measured in both groups.
resultsMost of the enrolled 45 PsA patient, were diagnosed with clinical enthesitis at least at one entheseal site (n = 43, 95.6%). However, on sonographic assessment, only 51.1% (n = 23) of the patients studied were classified with entheseal disease, MASEI ≥ 18. Achilles tendon was the most frequently involved entheseal site on clinical and ultrasonographic assessment. Total MASEI positively correlated with Disease Activity in Psoriatic Arthritis (DAPSA) (p = 0.047). Serum CLP was significantly higher in PsA patients (38.76 ng/mL) compared to healthy controls (31.07 ng/mL, p = 0.01). Serum CLP positively correlated with SPARCC, total MASEI and DAPSA (p = 0.002, 0.001 and 0.003, respectively). Serum CLP and MASEI were significantly lower in PsA patients on biological treatment compared to those on conventional treatment (p < 0.001).
conclusionsPsA patients with entheseal disease might have higher disease activity. Serum CLP showed potential association with disease activity and entheseal involvement in PsA patients.
Indexed as
Identifiers
42873410What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.